These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22151792)

  • 1. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
    Nguyen AT; Feasley CL; Jackson KW; Nitz TJ; Salzwedel K; Air GM; Sakalian M
    Retrovirology; 2011 Dec; 8():101. PubMed ID: 22151792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
    Urano E; Timilsina U; Kaplan JA; Ablan S; Ghimire D; Pham P; Kuruppu N; Mandt R; Durell SR; Nitz TJ; Martin DE; Wild CT; Gaur R; Freed EO
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
    Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
    Urano E; Ablan SD; Mandt R; Pauly GT; Sigano DM; Schneider JP; Martin DE; Nitz TJ; Wild CT; Freed EO
    Antimicrob Agents Chemother; 2016 Jan; 60(1):190-7. PubMed ID: 26482309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice.
    Keller PW; Adamson CS; Heymann JB; Freed EO; Steven AC
    J Virol; 2011 Feb; 85(4):1420-8. PubMed ID: 21106735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
    Lin Z; Cantone J; Lu H; Nowicka-Sans B; Protack T; Yuan T; Yang H; Liu Z; Drexler D; Regueiro-Ren A; Meanwell NA; Cockett M; Krystal M; Lataillade M; Dicker IB
    PLoS Pathog; 2016 Nov; 12(11):e1005990. PubMed ID: 27893830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of an HIV-1 maturation inhibitor on the structure and dynamics of CA-SP1 junction helices in virus-like particles.
    Gupta S; Louis JM; Tycko R
    Proc Natl Acad Sci U S A; 2020 May; 117(19):10286-10293. PubMed ID: 32341150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors.
    Ghimire D; Kc Y; Timilsina U; Goel K; Nitz TJ; Wild CT; Gaur R
    Retrovirology; 2021 Apr; 18(1):9. PubMed ID: 33836787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.
    Checkley MA; Luttge BG; Soheilian F; Nagashima K; Freed EO
    Virology; 2010 Apr; 400(1):137-44. PubMed ID: 20172577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site.
    Coric P; Turcaud S; Souquet F; Briant L; Gay B; Royer J; Chazal N; Bouaziz S
    Eur J Med Chem; 2013 Apr; 62():453-65. PubMed ID: 23399723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the mechanism of action of EP-39, a bevirimat derivative that inhibits HIV-1 maturation.
    Neyret A; Gay B; Cransac A; Briant L; Coric P; Turcaud S; Laugâa P; Bouaziz S; Chazal N
    Antiviral Res; 2019 Apr; 164():162-175. PubMed ID: 30825471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.
    Waki K; Durell SR; Soheilian F; Nagashima K; Butler SL; Freed EO
    PLoS Pathog; 2012; 8(11):e1002997. PubMed ID: 23144615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
    Adamson CS; Ablan SD; Boeras I; Goila-Gaur R; Soheilian F; Nagashima K; Li F; Salzwedel K; Sakalian M; Wild CT; Freed EO
    J Virol; 2006 Nov; 80(22):10957-71. PubMed ID: 16956950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.
    Nowicka-Sans B; Protack T; Lin Z; Li Z; Zhang S; Sun Y; Samanta H; Terry B; Liu Z; Chen Y; Sin N; Sit SY; Swidorski JJ; Chen J; Venables BL; Healy M; Meanwell NA; Cockett M; Hanumegowda U; Regueiro-Ren A; Krystal M; Dicker IB
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3956-69. PubMed ID: 27090171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
    Margot NA; Gibbs CS; Miller MD
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2345-53. PubMed ID: 20308382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
    Stoddart CA; Joshi P; Sloan B; Bare JC; Smith PC; Allaway GP; Wild CT; Martin DE
    PLoS One; 2007 Nov; 2(11):e1251. PubMed ID: 18043758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.
    Adamson CS; Sakalian M; Salzwedel K; Freed EO
    Retrovirology; 2010 Apr; 7():36. PubMed ID: 20406463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
    Kazennova EV; Vasil'ev AV; Bobkova MR
    Vopr Virusol; 2010; 55(3):37-41. PubMed ID: 20608080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
    DaFonseca S; Blommaert A; Coric P; Hong SS; Bouaziz S; Boulanger P
    Antivir Ther; 2007; 12(8):1185-203. PubMed ID: 18240859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
    Martin DE; Salzwedel K; Allaway GP
    Antivir Chem Chemother; 2008; 19(3):107-13. PubMed ID: 19024627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.